A Phase 3, Single Arm, Open Study to Assess the Immunogenicity and Safety of vYF in Adults Aged 18 Years and Over
Latest Information Update: 05 Nov 2025
At a glance
- Drugs SP 0218 (Primary)
- Indications Yellow fever
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
Most Recent Events
- 03 Nov 2025 New trial record